Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2024-08-15 Report Publication Anno…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 10Q - 30.06.2024
Report Publication Announcement Classification · 99% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli regulations and immediately follows up by stating: 'Attached hereto is a report on*Oramed Pharmaceuticals Inc. Form 10Q - 30.06.2024*'. A Form 10-Q is the standard SEC filing for quarterly financial reports. Since this document is an announcement *about* the attached 10-Q (and is relatively short, fitting the 'MENU VS MEAL' rule), it is classified as a Report Publication Announcement (RPA). If the attached PDF were analyzed, it would be classified as IR (Interim Report), but this wrapper document is the announcement itself.
2024-08-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2024
2024-08-14 English
CURRENT REPORT
Regulatory Filings
2024-08-02 English
The Company’s Board of Directors authorized a stock buyback program to purchase up to $20,000,000
Transaction in Own Shares Classification · 98% confidence The document is explicitly titled "FORM 8-K" and is a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934". Form 8-K reports major events that shareholders should know about. Item 8.01 details the authorization of a stock buyback program, which is a significant corporate action related to capital structure and share transactions. While the content relates to share repurchase (which aligns with POS), the filing format itself is a mandatory SEC current report (8-K). Since there is no specific code for Form 8-K, and the event is a transaction in own shares, the most specific applicable code is POS (Transaction in Own Shares). However, Form 8-K is a general regulatory filing. Given the options, POS is the most descriptive of the *event*, but 8-K filings often fall under RNS if the specific event type isn't listed. Since the event is explicitly a stock buyback program authorization, POS is the best fit among the provided specific codes for the *subject matter* of the filing, as it directly concerns the company buying back its own stock.
2024-06-26 English
The Company’s Board of Directors authorized a stock buyback program to purchase up to $20,000,000
Regulatory Filings Classification · 95% confidence The document is a filing notification from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange on 26/06/2024. The key indicator is the line: "Attached hereto is a report on *Form 8K*" followed by a filename. A Form 8-K is a report of unscheduled material events or corporate changes required by the SEC. Since this document is very short (1829 chars) and its primary function is to announce that a specific report (Form 8K) is attached or published, it fits the definition of a Report Publication Announcement (RPA) according to Rule 2, or potentially a general Regulatory Filing (RNS) if RPA is too specific for an 8-K announcement. Given the explicit mention of publishing a specific report, RPA is the most precise fit among the provided options, as it signals the release of another document.
2024-06-26 English
CURRENT REPORT
Regulatory Filings
2024-06-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.